Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 2:39 AM ET

Healthcare Equipment and Supplies

Company Overview of Oncimmune Limited

Company Overview

Oncimmune Limited develops and commercializes products for the detection of cancerous tumors. It offers EarlyCDT that detects and measures auto antibodies that immune system produces in response to antigens generated by cancerous tumors; and EarlyCDT-Lung, a blood test that detects the body's immune response in the form of antibodies to certain proteins produced by cancer cells. The company was incorporated in 2002 and is based in Nottingham, the United Kingdom.

Clinical Sciences Building

Nottingham City Hospital

Hucknall Road

Nottingham,  NG5 1PB

United Kingdom

Founded in 2002


44 1158 231 869


44 1158 231 958

Key Executives for Oncimmune Limited

Executive Chief Executive Officer and Director
Chief Financial Officer and Director
Chief Operational Scientist
Company Secretary
Clinical Director
Compensation as of Fiscal Year 2015.

Oncimmune Limited Key Developments

Oncimmune Announces the Appointment of James Jett as Chief Medical Officer

Oncimmune announced the appointment of Dr. James Jett, as Chief Medical Officer. Dr. Jett is currently Professor of Medicine in the Division of Oncology at National Jewish Health in the USA, where his research includes conducting clinical trials related to the screening and early detection of lung cancer. Prior to joining National Jewish Health in 2010, he held appointments as Professor of Medicine at Mayo Medical School and the University of Pittsburgh. Dr. Jett joins Oncimmune on January 1, 2016 and will be based in the US. He will support all aspects of the Company's research and development as Oncimmune continues the further commercialisation of EarlyCDT®-Lung on a global basis and the launch of new EarlyCDT® cancer tests.

Oncimmune Announces Appointment of Meinhard Schmidt as Non-Executive Chairman

Oncimmune announced the appointment of Meinhard Schmidt as Non-Executive Chairman. Meinhard has more than 25 years international experience as an entrepreneur and senior executive in the diagnostics and medical devices industries. Between 1998 and 2008 he was at Roche Diagnostics where he held various global senior leadership roles and was global Senior VP at Lab Diagnostics, which achieved the leading global position in the laboratory industry. Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, program and innovation management and has held executive management positions in Germany, The Netherlands, USA, Canada, Sweden, UK and Switzerland. He currently serves as Board Director at Sphere Medical PLC, valuationLAB AG, CeQur AG and as Chairman at Promimic AB.

Glycotest, Inc. Enters into a Research Collaboration with Oncimmune Ltd

NetScientific announced its portfolio company Glycotest, Inc. has entered into a research collaboration with Oncimmune Ltd. to explore the combined application of their proprietary tests in the early detection of liver cancer. Oncimmune has previously commercialised its proprietary autoantibody assay technology for the early detection of lung cancer with its EarlyCDT-Lung test and is now expanding this technology to the detection of liver cancer as well as other solid tumour cancers.  Glycotest is developing proprietary glycoprotein biomarkers and assay technology for the surveillance of serious liver diseases, including liver cancer. Under the terms of the agreement, Glycotest and Oncimmune will conduct a joint clinical evaluation of their combined tests, which could then be co-developed as agreed by the collaborators.

Similar Private Companies By Industry

Company Name Region
Acorus Therapeutics Ltd. Europe
Sartorius Stedim UK Limited Europe
Optimum Coatings Limited Europe
Cynosure UK Ltd Europe
Nordic Care Services Ltd. Europe

Recent Private Companies Transactions

June 7, 2015
Health Diagnostic Laboratory, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oncimmune Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at